Abstract
AbstractWe present results of peripheral blood stem cell (PBSC) mobilization, collection, and follow-up from 3928 consecutive unrelated stem cell donors. Assessments were performed prospectively at baseline, leukapheresis, 1 month, 6 months, and annually after PBSC donation. During follow-up, side effects were recorded by return post questionnaires. The median CD34+ cell counts on day 5 were 67.5/μL in male and 51/μL in female donors. Bone pain and headache were the most common side effects of recombinant human granulocyte-colony stimulating factor. Central venous access was required for 23 donations (0.6%). Throughout the follow-up, the absolute neutrophil counts were slightly below the initial baseline values but remained within the normal range. The majority of the donors reported good or very good health. Malignancies occurred in 12 donors (0.3%), among whom were 1 case of acute myeloid leukemia, 1 case of chronic lymphatic leukemia, and 2 cases of Hodgkin disease. Only the incidence of Hodgkin lymphoma differed significantly from an age-adjusted population. In conclusion, 7.5 μg/kg per day lenograstim proved to be safe and effective for mobilizing hematopoietic stem cells for allogeneic transplantation. Long-term monitoring of healthy PBSC donors remains important to guarantee the safety standards of PBSC mobilization and collection.
Highlights
The collection of hematopoietic stem cells mobilized from the bone marrow into the bloodstream of healthy donors has become a routine procedure throughout the world
The peripheral blood stem cell (PBSC) mobilization protocol was approved by the Ethics Committee of the University Hospital of Dresden, and donor informed consent was obtained in accordance with the Declaration of Helsinki
A single leukapheresis was sufficient to collect the CD34ϩ cell dose required in 3072 donors (78.2%)
Summary
The collection of hematopoietic stem cells mobilized from the bone marrow into the bloodstream of healthy donors has become a routine procedure throughout the world. The immediate side effects of rhG-CSF administration and PBSC collection have long been established; information as to possible long-term consequences has been limited up to now.[1] To reduce the risk of complications in healthy donors, the dose of rhG-CSF should be as low as possible. It is in the interests of both the donor and recipient to obtain enough stem cells to avoid graft failure. Our prospective study at the University Hospital of Dresden has evaluated the efficiency and consequences, both short- and longterm, of PBSC mobilization and harvesting in a large population of healthy unrelated donors
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
